Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | GFER | P55789 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3949041 | 0.86 | ESR1 (0.74) | ESR1ALDH1A1HTT | |
| SCHEMBL29555286 | 0.84 | CYP3A4 (0.50) | ESR1CYP3A4GFERALDH1A1TDP1 | |
| SCHEMBL15981416 | 0.80 | CYP3A4 (0.46) | ESR1CYP3A4GFERALDH1A1TDP1 | |
| SCHEMBL415571 | 0.78 | TDP1 (0.44) | ESR1CYP3A4GFERALDH1A1TDP1 | |
| SCHEMBL986310 | 0.76 | ESR1 (0.61) | ESR1ALDH1A1TDP1MAPTCYP19A1 | |
| Boric Acid SCHEMBL29504203 | 0.76 | ESR1 (0.68) | ESR1 | |
| SCHEMBL3211356 | 0.75 | GFER (0.59) | CYP3A4GFERALDH1A1TDP1TSHR | |
| SCHEMBL19065738 | 0.74 | ESR1 (0.58) | ESR1ALDH1A1MAOBCYP19A1CYP11B1 | |
| SCHEMBL10712863 | 0.74 | ESR1 (1.00) | ESR1CYP3A4ALDH1A1MAPTMEN1 | |
| SCHEMBL18694997 | 0.74 | ESR1 (0.58) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | claimed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | claimed |
| EP-1737471-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND Pharmaceuticals (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005102358-A2 | SILICONE-SUBSTITUTED COX-2 SELECTIVE INHIBITORS | RND PHARMACEUTICALS (US) | 2005-11-03 | — | — | WO | claimed |
| CN-104977804-A | Positive photosensitive resin composition, photosensitive resin film and display device using the same | SAMSUNG SDI CO LTD | 2015-10-14 | — | — | CN | disclosed |
| CN-104730861-A | Positive photosensitive resin composition, photosensitive resin film prepared by using the same, and display device | SAMSUNG SDI CO LTD | 2015-06-24 | — | — | CN | disclosed |
| CN-102566274-B | Positive photosensitive resin composition, photosensitive resin film prepared by using same, and semiconductor device including photosensitive resin film | CHEIL IND INC | 2014-05-07 | — | — | CN | disclosed |
| US-7964738-B2 | Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives | SILAMED, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20090306015-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | SILAMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-1968609-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | RND Pharmaceuticals, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1919929-A4 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS INC (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007073560-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | RND PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | US | disclosed |
| WO-2007019221-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1737471-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | RND Pharmaceuticals (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005102358-A2 | SILICONE-SUBSTITUTED COX-2 SELECTIVE INHIBITORS | RND PHARMACEUTICALS (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | ESR1 2630/4885CYP3A4 1106/4885GFER 2153/4885 |
| US-20070129331-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF LIPOPHILIC, SILICON-SUBSTITUTED, CYCLOOXYGENASE-2 SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND DERIVATIVES | PTGES2, PTGS2, SI | ESR1 253/4885CYP3A4 486/4885GFER 2458/4885 |
| US-20090306015-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF HIGHLY LIPOPHILIC SULFHYDRYL COMPOUNDS | SI, SCLY, SGMS1 | ESR1 3526/4885CYP3A4 276/4885GFER 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.